Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FES-PET/CT Companion to FORESEE
NCT04727632Phase 1Terminated
- Sponsor
- University of Utah
- Start
- Mar 2021
- Primary completion
- Sep 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by University of Utah. Primary endpoint: Number of patients on the FORESEE trial refractory to all combinatorial hormonal therapies that are recruited and imaged with FES-PET/CT prior to switching to non-hormonal therapeutic agents at 12 weeks. Started Mar 2021; status: terminated.
Beyond the preview
Go deeper on NCT04727632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727632.